pharmadog
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
Hubs
  • Topics
  • Patent cliff
  • Publications
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
pharmadog news

Browse

827 stories matching this filter · ← front page

★ save view↓export CSV
rangeto
sort
recentoldestsourcealpha
source
STAT776Endpoints580BioPharma Dive223onclive165Fierce Biotech54BioSpace52raps24
therapy area
allOncology81Cardiology27Psychiatry & CNS21Vaccines17Immunology17Rare Disease12Hepatology6
  • HMNC Brain Health raises $50M Series B to advance two depression drugs
    HMNC Brain Health has secured $50 million in a Series B fundraise designed to support two psychiatry programs into mid-stage studies. The family-owned German drugmaker Medice led the Series B, wh…
    Endpoints · 1mo ago↗ source
  • Biopharma’s 2025 industry pay report; Parabilis sets industry record IPO; and more
    Welcome back to Endpoints Weekly! This week, we opened nominations for our eighth annual Women in Biopharma report. We’re looking to profile 20 scientists, executives, founders and other enterprisi…
    Endpoints · 1mo ago↗ source
  • Merck brings Welireg-Keytruda combo to treat kidney cancer
    Merck’s Welireg and Keytruda combination won approval as an adjuvant treatment for kidney cancer patients after surgery to remove all or part of the organ. The combination was approved Friday for…
← prev
page 15 of 34
next →
Hematology6
Pulmonology5
Infectious Disease4
Ophthalmology3
Dermatology2
Endpoints · 1mo ago
↗ source
  • Amgen and the FDA want two different outcomes for Tavneos. What will patients do?
    Amgen has asked the FDA to review evidence that its drug Tavneos (avacopan), which treats a rare form of vasculitis, is worth keeping on the market, as the future of the drug remains in flux. ...
    Endpoints · 1mo ago↗ source
  • Eli Lilly invests in startup Abridge for clinical trial recruitment
    Eli Lilly has invested in Abridge as the health tech startup expands into clinical trial recruitment and broadens its reach into the life sciences. The investment, made through Lilly’s venture ar…
    Endpoints · 1mo ago↗ source
  • Enliven prices $400M offering; Jazz drug Zepzelca fails confirmatory study
    Plus news about Caribou, Adial, and the Beneluxa Initiative. 💵 Enliven Therapeutics’ data and raise: The Burlingame, CA-based biotech priced a $400 million offering {$ELVN} Thursday night after…
    Endpoints · 1mo ago↗ source
  • Biopharma's pay oddities of 2025: Executive perks and eccentricities
    In combing through thousands of C-suite pay packages worth billions of dollars, it’s rare for a line item to stick out. Every once in a while, a biopharma company discloses perks that go beyond t…
    Endpoints · 1mo ago↗ source
  • Rapport ‘fully prepared’ to launch seizure drug solo, CEO says
    <p>In a wide-ranging interview, Abe Ceesay detailed how Rapport built an investor syndicate and why the company is confident it can join the ranks of successful, commercial-stage brain drugmakers.</p>
    BioPharma Dive · 1mo ago↗ source
  • WuXi AppTec sues Pentagon in challenge over inclusion on Chinese military list
    WuXi AppTec has lodged a claim against the Department of Defense following its addition to a list of companies associated with the Chinese military. Under the complaint, filed Thursday with the U…
    Endpoints · 1mo ago↗ source
  • GSK took advantage of ASCO dip to get discount on Nuvalent
    GSK’s $10.6 billion buyout of Nuvalent, announced Tuesday, was the largest in the company’s history. But did new CEO Luke Miels get a discount? At $124 a share, the price Miels paid ...
    Endpoints · 1mo ago↗ source
  • Novo's M&A leader leaves for Forbion; Perrigo CEO's 'personal conduct' issues led to resignation
    Forbion’s portfolio companies have been no stranger to M&A deals in recent years. But the Dutch investment firm now wants more of its biotechs to benefit from the industry’s ...
    Endpoints · 1mo ago↗ source
  • Sciwind has two Western partners for its obesity drug, but is open to more
    Sciwind Biosciences has already licensed its GLP-1 obesity drug ecnoglutide twice over — to Pfizer and Verdiva Bio — but it is not done yet. The Chinese biotech is seeking new partners for the ri…
    Endpoints · 1mo ago↗ source
  • The seeming inevitability of rising healthcare costs
    We’re getting our first signs of where healthcare costs are heading next year. According to a survey of actuaries at 27 health plans covering employers and individuals on the exchanges
    Endpoints · 1mo ago↗ source
  • Summit pulls $500M share sale a day after announcing it
    <figure><div><img src="https://imgproxy.divecdn.com/_dT9zKJsCoS0jrFraV8Vdkcut5aCVtKPN0y1PuLlKnE/g:ce/rs:fill:1600:900:1/Z3M6Ly9kaXZlc2l0ZS1zdG9yYWdlL2RpdmVpbWFnZS9HZXR0eUltYWdlcy0xMTUwMzE2NTA1LmpwZ…
    BioPharma Dive · 1mo ago↗ source
  • Drugmakers are turning to logistics providers as trade disruptions linger, DHL exec says
    DHL is in discussions with multiple major drugmakers who are looking for the logistics company to either take over their sites or access its resources, the company’s supply chain business CEO Hendr…
    Endpoints · 1mo ago↗ source
  • Sensorion, citing Regeneron competition, shifts focus to a different hearing loss therapy
    <figure><div><img src="https://imgproxy.divecdn.com/Sl1QCaU_supqAvtEJA_tXhY8sXexPvdgos3TT-jjIM4/g:ce/rs:fill:1600:900:1/Z3M6Ly9kaXZlc2l0ZS1zdG9yYWdlL2RpdmVpbWFnZS9HZXR0eUltYWdlcy0xMjA1MzM4Nzg3LmpwZ…
    BioPharma Dive · 1mo ago↗ source
  • Summit withdraws $500M offering, citing 'market conditions'
    The current biotech environment can apparently support an industry-record IPO and simultaneously hamper efforts to raise half a billion dollars. Summit Therapeutics ditched plans for a $500 milli…
    Endpoints · 1mo ago↗ source
  • Sensorion axes hearing loss program; Novartis' biomarker data in muscular dystrophy
    Plus, news about Imaavy. 👂 Sensorion selects one hearing loss program, axes another: The biotech is ending the development of SENS-501 for OTOF-related hearing loss following a “strategic revie…
    Endpoints · 1mo ago↗ source
  • Camurus’ second CRL for acromegaly drug; Teva details workforce cuts
    Plus, news about a drug shortages report and Axplora: 🛑 Camurus has been hit with a second CRL: The rejection is for the drug CAM2029 in acromegaly due to problems at a third-party manufacturer.…
    Endpoints · 1mo ago↗ source
  • Novartis RNA drug acquired in $12B Avidity deal notches a trial win
    <p>The data showed that del-brax, an “antisense oligonucleotide conjugate” being tested against a muscle-wasting disease, met its primary endpoint in a Phase 1/2 study.</p>
    BioPharma Dive · 1mo ago↗ source
  • Biopharma pay report: Top-paid CSOs, CMOs of 2025
    Biopharma’s top scientists and doctors don’t make nearly as much as CEOs, but some still took in eight-figure pay packages in 2025. As part of our series on industry compensation, Endpoints News…
    Endpoints · 1mo ago↗ source
  • Kardigan plans $320M IPO for heart drugs as Nasdaq listings gain steam
    Parabilis Medicines' record-breaking IPO will be a tough act to follow, but a drug developer with three late-stage cardio medicines is up for the challenge. It's led by a CEO who sold ...
    Endpoints · 1mo ago↗ source
  • J&J looks to widen Imaavy’s use; $300M backs rare disease drug launch
    <figure><div><img src="https://imgproxy.divecdn.com/idsdMAHsPbXObDUtQW2qRG7uveBUVv6HCTn9NTtlDOI/g:nowe:0:0/c:1207:682/rs:fill:1600:900:1/Z3M6Ly9kaXZlc2l0ZS1zdG9yYWdlL2RpdmVpbWFnZS9HZXR0eUltYWdlcy0x…
    BioPharma Dive · 1mo ago↗ source
  • Takeda's plaque psoriasis pill beats Bristol Myers' Sotyktu in Phase 3
    Takeda’s $4 billion bet on an oral plaque psoriasis drug has paid off again, as the company reported the pill beat Bristol Myers Squibb’s Sotyktu in a head-to-head Phase 3 study. Zasocitinib indu…
    Endpoints · 1mo ago↗ source
  • Neion Bio raises $23M Series A to make proteins from chicken eggs
    Neion Bio has secured an oversubscribed $23 million Series A to further develop its technology that uses chicken eggs to make active pharmaceutical ingredients for biologic drugs. The funding rou…
    Endpoints · 1mo ago↗ source